MediciNova completes enrolment for phase 2 clinical trial of ibudilast to treat recurrent and newly diagnosed glioblastoma

pharmafile | January 13, 2023 | News story | Research and Development  

Biopharmaceutical company MediciNova has announced that its phase 2 clinical trial to assess MN-166 (ibudilast) for the treatment of recurring and newly diagnosed glioblastoma, which is to be conducted at Dana-Farber Cancer Institute, has finished enrolling patients.

The phase 1/2 trial has been divided into two parts: the first being a dose-escalation phase, and the second a fixed-dose phase. Part 1 was intended to evaluate the safety and tolerability of an escalating dose of the drug when given in combination with temozolomide (TMZ), determining a safe dose to be used in part 2. Part 2 of the study intends to evaluate the drug’s efficacy when used alongside TMZ.

The company is also expected to assess the combination therapy on tumour tissue analysis, as tumour tissues were obtained from certain surgeries and biopsies. Preliminary tumour tissue analysis and clinical findings from part 1 of the study are expected to be presented at the 20th Annual World Congress of Society for Brain Mapping and Therapeutics (SBMT) to be held on 16 – 19 February 2023.

Kazuko Matsuda, MD, PhD, MPH, chief medical officer of MediciNova, commented: “We have completed enrolment and are actively treating the remaining patients in part 2 of the trial. We look forward to reporting the interesting findings from tumour tissue analysis and clinical outcomes at the 20th Annual World Congress of SBMT, including potential predictors of treatment response to MN-166 plus TMZ combination therapy in glioblastoma. We will release more information after SBMT meeting.”


Betsy Goodfellow

Related Content

No items found

Latest content